The prognostic value of α-thymosins in breast cancer

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1501-1508

  Tsitsilonis, Ourania E ^a   Bekris, Efstathios ^b   Voutsas, Ioannis F ^a   Baxevanis, Constantin N ^a   Markopoulos, Christos ^c   Papadopoulou, Sophia Areti ^c   Kontzoglou, Kostas ^c   Stoeva, Stanka ^d   Gogas, John ^c   Voelter, Wolfgang ^d   Papamichail, Michael ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

thymosins; Breast cancer; Parathymosin ; Prognostic factors; Prothymosin

Indexed keywords

PARATHYMOSIN; PROTHYMOSIN ALPHA; THYMOSIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST LESION; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CROSS REACTIONS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOIMMUNOASSAY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; THYMOSIN;

EID: 15444352708     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Henderson BE, Ross RK and Pike MC: Towards the primary prevention of cancer. Science 254: 1131-1138, 1991.
2. Gusterson BA. Prognostic variables and future predictors of behaviour and response. In: Adjuvant Therapy of Breast Cancer (Senn H-J, Goldhirsch A, Gelber RD and Thurlimann B, eds). Berlin, V. Springer Verlag, 1996, pp 87-89
3. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedoussis GVZ, Missitzis I, Papamichail M: Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphocyte-activated killer function in patients with breast cancer. Cancer 72: 491-501, 1993.
4. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Beroukas C, Stathopoulos GP and Papamichail M: Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Cancer 76: 1253-1260, 1995.
5. Mitchell MS: Immunology and immunotherapy of breast cancer. In: Diseases of the Breast (Harris JR, Hellman S, Lippman M and Morrow M, eds). Philadelphia, JB Lippincott, 1995, pp 15-65.
6. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID and Harris AL: Differential expression of the topoisomerase II α and β genes in human breast cancers. Br J Med 73: 1518-1524, 1996.
7. Clark GM, Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D and McGuire WL: How to integrate steroid hormone receptor, flow cytometric and other prognostic information in regard to primary breast cancer. Cancer 71: 2157-2162, 1993.
8. Tandon AK, Clark GM, Chamness GC, Chirwin JM and McGuire WL: Cathepsin D and prognosis in breast cancer. N Eng J Med 322: 297-302, 1990.
9. Schonborn I, Minguillon C, Mohner M and Ebeling K: PCNA as a potential prognostic marker in breast cancer. The Breast 3: 97-102, 1996.
10. Gandolfo GM, Conti L and Vercillo M: Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. Anticancer Res 16: 2155-2159, 1996.
11. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA and Robertson JF: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16: 927-930, 1996.
12. Haritos AA: α-Thymosins: Relations in Structure, Distribution and Function. In: Isozymes: Current Topics in Biological and Medical Research (Ratazzi M, Scandalios J and Whitt G, eds). New York, Alan R. Liss Inc., 1987, Vol. 14, pp 123-152.
13. Baxevanis CN, Reclos GJ and Papamichail M: Prothymosin a restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer. Int J Cancer 53: 264-268, 1993.
14. Baxevanis CN, Thanos D, Reclos GJ, Anastasopoulos E, Tsokos GC, Papamatheakis J and Papamichail M: Prothymosin a enhances human and murine MHC class II surface antigen expression and messenger RNA accumulation. J Immunol 148: 1979-1984,1992.
15. Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis O and Papamichail M: Induction of tumor-specific T lymphocyte responses in vivo by prothymosin α. Cancer Immunol Immunother 40: 410-418, 1995.
16. Tsitsiloni OE, Stiakakis J, Koutselinis A, Gogas J, Markopoulos Ch, Yialouris P, Bekris S, Panoussopoulos D, Kiortsis V, Voelter W and Haritos AA: Expression of α-thymosins in human tissues in normal and abnormal growth. Proc Natl Acad Sci USA 90: 9504-9507, 1993.
17. Conteas CN, Mutchnick MG, Palmer KC, Weller FE, Luk GD, Naylor PH, Erdos MR, Goldstein AL, Panneerselvam C and Horecker BL: Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: Evidence for a nuclear site of action. Proc Natl Acad Sci USA 87: 3269-3273,1990.
18. Dominguez F, Magdalena C, Carcio E, Roson E, Paredes J, Loidi L, Zalvide J, Fraga M, Forteza J, Regueiro BJ and Puente JL: Tissue concentrations of prothymosin alpha: a novel proliferation index of primary breast cancer. Eur J Cancer 29: 893-897, 1993.
19. Szabo P, Ehleiter D, Whittington E and Weksler ME: Prothymosin α expression occurs during G1 in proliferating B or T lymphocytes. Biochem Biophys Res Comm 185: 953-959, 1992.
20. Manrow RE, Sburlati AR, Hanover JA and Berger SL: Nuclear targeting of prothymosin α. J Biol Chem 266: 3916-3924, 1991.
21. Papamarkaki T and Tsolas O: Prothymosin a binds to histone H1 in vitro. FEBS Lett 345: 71-75, 1994.
22. Sburlati AR, Manrow RE and Berger SL: Prothymosin α antisense oligomers inhibit myeloma cell division. Proc Natl Acad Sci USA 88: 253-257, 1991.
23. Vareli K, Frangou-Lazaridis M and Tsolas O: Prothymosin α mRNA levels vary with c-myc expression during tissue proliferation, viral infection and heat shock. FEBS Lett 371: 337-340, 1995.
24. Tsitsiloni OE, Heimer E, Felix A, Yialouris PP, Vamvoukakis J, Voelter W and Haritos AA: Radioimmunoassays for the C-terminus of prothymosin α and the N-terminus of parathymosin α for the measurement of the levels of α-thymosins in human cancer. J Immunol Meth 169: 163-171, 1994.
25. Stalsberg H, Thomas DB, Noonan EA and the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Histologic types of breast carcinoma in relation to international variation and breast risk factors. Int J Cancer 44: 399-409, 1989.
26. Yialouris PP, Evangelatos GP, Soteriadis-Vlahos C, Heimer EP, Felix AM, Tsitsiloni OE and Haritos AA: The identification of prothymosin α-like material in vertebrate lymphoid organs by a radioimmunoassay for the N-terminal decapeptide. J Immunol Meth 106: 267-275, 1988.
27. Gomez-Marquez J, Segade F, Dosil M, Pichel JG, Bustelo XR and Freire M: The expression of prothymosin α gene in T lymphocytes and leukemic lymphoid cells is tied to lymphocyte proliferation. J Biol Chem 264: 8451-8454, 1989.
28. Schonborn I, Minguillon C, Mohner M and Ebeling K: PCNA as a potential prognostic marker in breast cancer. The Breast 3: 97-102 1994.
29. Collett K, Maehle BO, Skjaerven R and Aas T: Prognostic role of oestrogen, progesterone and androgen receptor in relation to patient age in patients with breast cancer. The Breast 5: 123-126, 1996.
30. Kuhajda FP, Piantadosi S and Pasternack GP: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N Engl J Med 321: 636-641, 1989.
31. Robertson JFR: The role of serum tumor markers in breast cancer. The Breast 4: 62-63, 1995.
32. Panneerselvam C, Haritos AA, Caldarella J and Horecker BL: Prothymosin α in human blood. Proc Natl Acad Sci USA 84: 4465-4469, 1987.
33. Tsitsilonis OE, Trichopoulou E, Roumeliotou A, Voelter W and Papaevangelou G: Study of α-thymosins in AIDS. Hellen Arch AIDS 3: 380-386, 1995.
34. Mastino A, Favalli C, Grelli S, Rasi G, Pica F, Goldstein AL and Garaci E: Combination therapy with thymosin α1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 50: 493-499, 1992.
35. Verghese-Nikolakaki S, Apostolikas N, Livaniou E, Ithakissios DS and Evangelatos GP: Preliminary findings on the expression of thymosin beta-10 in human breast cancer. Brit J Cancer 74: 1441-1444, 1996.